Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines

PHASE4CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

December 15, 2022

Study Completion Date

December 15, 2023

Conditions
Immune ResponseSafety
Interventions
BIOLOGICAL

bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine

The bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine is a combination of 15-µg of mRNA encoding the wild-type (WT) spike protein and 15-µg of mRNA encoding the spike protein of the Omicron BA.4/BA.5 subvariant.

BIOLOGICAL

quadrivalent influenza vaccine

The quadrivalent influenza vaccine is an inactivated vaccine containing 15μg HA/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2022-2023 northern hemisphere season

Trial Locations (1)

22711

International St. Mary's hospital, Incheon

All Listed Sponsors
collaborator

Korea University Guro Hospital

OTHER

lead

Catholic Kwandong University

OTHER